<DOC>
	<DOCNO>NCT01717248</DOCNO>
	<brief_summary>The purpose study evaluate safety GCS-100 treatment chronic kidney disease .</brief_summary>
	<brief_title>Safety Study GCS-100 Treat Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Subject capable understand purpose risk study able provide write Informed Consent . 2 . Subject male female , age &gt; =18 &lt; = 75 . Patients older 75 y/o include request investigator discretion Medical Monitor . 3 . Adult patient chronic kidney disease longer 12 month stable opinion investigator past 3 month 4 . Systolic blood pressure &lt; =160 mm Hg &gt; = 90 mm Hg 2 reading . Diastolic blood pressure &lt; = 100 mm Hg &gt; = 40 mm Hg 2 reading least one screen visit . 5 . Subject willing practice birth control . 6 . Subject willing able comply protocol requirement . 7 . Subject measureable level galectin3 concentration plasma time prior entry . 8 . Subject glomerular filtration rate 1545 mL/min/1.73 m2 determine use CKDEPI equation ( see section 3.6.1 ) 9 . Subject 's clinical laboratory value : 1 . Hemoglobin ≥9 g/dL 2 . Total bilirubin ≤ 1.5 X Institutional Upper Limit Normal ( IULN ) 3 . AST and/or ALT ≤ 2.5 X upper limit normal 10 . Female subject childbearing potential ( i.e. , woman surgically sterilize postmenopausal least 1 year ) male subject partner childbearing potential must agree use medically acceptable method contraception throughout study period . 1 . Subjects treatment experimental ( unlicensed ) drug within 4 week ≤ 5 halflives prior treatment GCS 100 . 2 . Subjects kidney disease due systemic lupus erythematosus ( regardless whether active remission ) , form vasculitis ( regardless whether active remission ) , IgA nephropathy , multiple myeloma , polycystic kidney disease , untreated obstruct nephropathy cause opinion investigator may put subject increase risk 3 . Subject expect start renal replacement therapy kind within 6 month enrollment 4 . Subjects previous solid organ transplant 5 . Subject undergoing treatment immunosuppression agent except topical agent inhaled steroid condition chronic stable . 6 . Subject know history cancer within past 5 year prior enrollment exclude nonmelanoma skin cancer actively treat 7 . Subject known history human immunodeficiency virus infection , active hepatitis C , active hepatitis B , prior history infection hepatitis B ( HBcAb positive ) . Medical Monitor may approve adequate hepatic function document patient without evidence cirrhosis subject HCV prior history hepatitis B , include , limited liver biopsy . 8 . Subject clinically relevant active infection and/or serious comorbid medical condition recent myocardial infarction ( within last 6 month ) , unstable angina , difficulttocontrol congestive heart failure , uncontrolled hypertension , difficulttocontrol cardiac arrhythmia , chronic obstructive chronic restrictive pulmonary disease , and/or cirrhosis . 9 . Subject major surgery within 4 week prior Study Day 1 . 10 . If female , subject pregnant breastfeeding . 11 . Subject concomitant disease condition , include laboratory abnormality , opinion Investigator could interfere conduct study could put subject unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>